Printer Friendly

Biomoda Inc adds Waterbury Pulmonary Associates Research as enrolment site for lung cancer study.

M2 EQUITYBITES-January 13, 2011-Biomoda Inc adds Waterbury Pulmonary Associates Research as enrolment site for lung cancer study(C)2011 M2 COMMUNICATIONS http://www.m2.com

Cancer diagnostics company Biomoda Inc (OTCBB:BMOD.ob) said on Wednesday that it has added Waterbury Pulmonary Associates Research as as enrolment site for the former's pilot clinical study of CyPath diagnostic assay.

The company stated that Waterbury Pulmonary Associates Research is enrolling participants for the positive control group, patients diagnosed with lung cancer who have not yet started treatment.

Waterbury Pulmonary Associates Research, based in Waterbury, CT, is the clinical research arm of a pulmonary and critical care practice pulmonary and critical care group.

According to the report, Dr David G. Hill, director of clinical research at Waterbury Pulmonary, will serve as the local Principal Investigator (PI) for Biomoda's study. Additionally, Dr Thomas L. Bauer, national PI of the Biomoda study, will continue to oversee collection of samples in the positive control group at the Helen F. Graham Cancer Center, Christiana Care Health System, in Newark, DE.

This protocol for Waterbury Pulmonary's participation in the Biomoda study was approved by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board.

Biomoda's CyPath assay is reportedly based on a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. The company is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. Pending FDA approval, CyPath is for investigational use only.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Clinical report
Date:Jan 13, 2011
Words:259
Previous Article:-Two brokers axe price targets on Danish Carlsberg.
Next Article:-Denmark industrial output edges down in Nov 2010.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters